Novartis International AG http://www.novartis.com Novartis delivers excellent performance in third quarter: recently launched products generate 20%* of sales; Gilenya approved; Alcon consolidated 2010-10-21T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1453762.shtml Novartis obtains CHMP positive opinion for its investigational pre-pandemic influenza vaccine Aflunov® to help protect against (H5N1) avian influenza 2010-09-24T17:38:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1446813.shtml Novartis receives EU approval recommendation for TOBI® Podhaler®, a fast and simple therapy that helps reduce treatment burden for cystic fibrosis patients 2010-09-24T15:16:39 CET http://www.novartis.com/newsroom/media-releases/en/2010/1446760.shtml Novartis study shows Onbrez® Breezhaler® is superior to salmeterol in reducing breathlessness for patients with COPD 2010-09-19T14:40:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1445166.shtml Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation, growth and productivity 2010-04-20T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1405499.shtml Novartis receives approval in the European Union for Onbrez® Breezhaler®, a new once-daily bronchodilator for patients with COPD 2009-12-03T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1358846.shtml Basel, December 3, 2009 - Novartis announced today that the European Commission (EC) has approved Onbrez Breezhaler (QAB149 or indacaterol) in both 150 mcg and 300 mcg doses as a new once-daily maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). Novartis receives Complete Response letter from FDA for QAB149, an investigational bronchodilator for COPD 2009-10-19T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1348153.shtml Basel, October 19, 2009 - Novartis has received a Complete Response letter from the US Food and Drug Administration (FDA) as part of the US regulatory review for QAB149 (indacaterol), an investigational once-daily bronchodilator for the treatment of adult patients with chronic obstructive pulmonary disease (COPD). Novartis bronchodilator QAB149 recommended for approval in European Union to treat patients with chronic obstructive pulmonary disease 2009-09-25T17:20:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1343682.shtml Basel, September 25, 2009 - Novartis has received a positive opinion recommending European Union (EU) approval of QAB149 (indacaterol) for maintenance bronchodilator treatment in adult patients with chronic obstructive pulmonary disease (COPD). When approved, QAB149 and its device, Concept-1, will be known as Onbrez® Breezhaler®[§]. Novartis investigational bronchodilator QAB149 improves lung function and reduces breathlessness compared to tiotropium in patients with COPD 2009-09-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1341238.shtml Disclaimer Novartis receives approval in EU for Xolair® to treat children age 6 to 11 years suffering from severe persistent allergic asthma 2009-08-24T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1336542.shtml About Novartis Novartis delivers strong operational performance in the first half of 2009 driven by sustained Pharmaceuticals innovation 2009-07-16T06:59:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1329090.shtml Basel, July 16, 2009 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis, said: I am pleased that our pharmaceuticals business continues to deliver double-digit underlying growth, driven by the strong momentum of our recently launched products. Our pipeline continues to deliver a steady stream of innovative medicines. In the first six months of 2009 we have introduced our new anti-cancer therapy Afinitor in the US and gained first approval for llaris as a new biologic therapy for auto-inflammatory diseases. We are advancing well in our efforts to rapidly produce and commercialize a vaccine against the H1N1 virus, with clinical trials set to begin in July. We continue to expect record underlying results in constant currencies based on innovation and productivity initiatives. Novartis announces restructuring of global collaboration with Schering-Plough to develop fixed-dose combination respiratory therapies 2009-05-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1316055.shtml Basel, May 19, 2009 - Novartis has assumed exclusive worldwide rights to develop and commercialize QMF149, a fixed-combination of its investigational QAB149 (indacaterol) with Schering-Plough Corporation's inhaled corticosteroid mometasone, in changes announced today to the companies' collaboration to develop fixed-dose combination respiratory therapies. Novartis: excellente performance opérationnelle au premier semestre 2009, entraînée par les innovations soutenues de Pharmaceuticals 2009-07-16T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2009/1329097.shtml Bâle, le 16 juillet 2009 - En commentant les résultats, le DrDaniel Vasella, Président et Administrateur délégué de Novartis a déclaré: «Je suis heureux de voir que nos activités pharmaceutiques continuent de progresser au rythme d'une croissance sous-jacente à deux chiffres, sous la forte impulsion des produits lancés récemment. Tandis que notre pipeline émet un flux continu de médicaments innovants. Au cours des six premiers mois de 2009, nous avons lancé Afinitor, notre nouveau traitement anticancer aux Etats-Unis où nous avons également obtenu une première homologation pour Ilaris, un nouveau traitement biologique pour un groupe de maladies auto-inflammatoires. Nous avançons rapidement vers la production et la commercialisation d'un vaccin contre le virus H1N1, dont les essais cliniques commenceront en juillet. Nous prévoyons toujours de réaliser des résultats sous-jacents records en monnaies constantes, grâce à l'innovation et aux gains de productivité». Novartis erzielt im ersten Halbjahr 2009 eine starke operative Performance - dank der anhaltenden Innovationskraft der Division Pharmaceuticals 2009-07-16T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2009/1329092.shtml Erstes Halbjahr